An in vitro study on the effects of nisin on the antibacterial activities of 18 antibiotics against Enterococcus faecalis

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Tong, Zhongchun ^a   Zhang, Yuejiao ^a   Ling, Junqi ^a   Ma, Jinglei ^a   Huang, Lijia ^a   Zhang, Luodan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CALCIMYCIN; CEFAZOLIN; CEFEPIME; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LINEZOLID; METRONIDAZOLE; NISIN; PENICILLIN DERIVATIVE; POLYMYXIN; ROXITHROMYCIN; STREPTOMYCIN; SULFAPYRIDINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BIOASSAY; BIOFILM; CHECKERBOARD ASSAY; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; IN VITRO STUDY; MICROBIAL MORPHOLOGY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TRANSMISSION ELECTRON MICROSCOPY; DRUG EFFECTS; DRUG INTERACTION; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; BIOFILMS; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; NISIN;

EID: 84895895268     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089209     Document Type: Article

References (49)

1. Sengupta S, Chattopadhyay MK, Grossart HP (2013) The multifaceted roles of antibiotics and antibiotic resistance in nature. Front Microbiol 4: 47.
2. Palmer AC, Kishony R (2013) Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance. Nat Rev Genet 14: 243-248.
3. Jenssen H, Hamill P, Hancock RE (2006) Peptide antimicrobial agents. Clin Microbiol Rev 19: 491-511. (Pubitemid 44137212)
4. Hadley EB, Hancock RE (2010) Strategies for the discovery and advancement of novel cationic antimicrobial peptides. Curr Top Med Chem 10: 1872-1881.
5. Severina E, Severin A, Tomasz A (1998) Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens. J Antimicrob Chemother 41: 341-347.
6. FDA (1988) Food and Drug Administration. Nisin preparation: Affirmation of GRAS status as a direct human food ingredient. 11251 ed.
7. Naghmouchi K, Le Lay C, Baah J, Drider D (2012) Antibiotic and antimicrobial peptide combinations: synergistic inhibition of Pseudomonas fluorescens and antibiotic-resistant variants. Res Microbiol 163: 101-108.
8. Mataraci E, Dosler S (2012) In vitro activities of antibiotics and antimicrobial cationic peptides alone and in combination against methicillin-resistant Staphylococcus aureus biofilms. Antimicrob Agents Chemother 56: 6366-6371.
9. Dosler S, Gerceker AA (2012) In vitro activities of antimicrobial cationic peptides; melittin and nisin, alone or in combination with antibiotics against Gram-positive bacteria. J Chemother 24: 137-143.
10. Dosler S, Gerceker AA (2011) In vitro activities of nisin alone or in combination with vancomycin and ciprofloxacin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains. Chemotherapy 57: 511-516.
11. Naghmouchi K, Baah J, Hober D, Jouy E, Rubrecht C, et al. (2013) Synergistic effect between colistin and bacteriocins in controlling Gram-negative pathogens and their potential to reduce antibiotic toxicity in mammalian epithelial cells. Antimicrob Agents Chemother 57: 2719-2725.
12. Richards MJ, Edwards JR, Culver DH, Gaynes RP (2000) Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 21: 510-515. (Pubitemid 30647154)
13. Hollenbeck BL, Rice LB (2012) Intrinsic and acquired resistance mechanisms in enterococcus. Virulence 3: 421-433.
14. Tong Z, Ling J, Lin Z, Li X, Mu Y (2013) The Effect of MTADN on 10 Enterococcus faecalis Isolates and Biofilm: An In Vitro Study. J Endod 39: 674-678.
15. Clinical and Laboratory Standards Institute (2006) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7; 7th ed. Clinical Laboratory Standards Institute, Wayne, PA.
16. Andrews JM (2001) Determination of minimum inhibitory concentrations. J Antimicrob Chemother 48 Suppl 1: 5-16.
17. Ouhara K, Komatsuzawa H, Kawai T, Nishi H, Fujiwara T, et al. (2008) Increased resistance to cationic antimicrobial peptide LL-37 in methicillin-resistant strains of Staphylococcus aureus. J Antimicrob Chemother 61: 1266-1269. (Pubitemid 351753592)
18. Tong Z, Zhou L, Jiang W, Kuang R, Li J, et al. (2011) An in vitro synergetic evaluation of the use of nisin and sodium fluoride or chlorhexidine against Streptococcus mutans. Peptides 32: 2021-2016.
19. Odds FC (2003) Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother; 52: 1.
20. Dufour M, Manson JM, Bremer PJ, Dufour JP, Cook JM, et al. (2007) Characterization of monolaurin resistance in Enterococcus faecalis. Appl Environ Microbiol 73: 5507-5515. (Pubitemid 47378755)
21. Vickerman MM, Flannagan SE, Jesionowski AM, Brossard KA, Clewell DB, et al. (2010) A genetic determinant in Streptococcus gordonii Challis encodes a peptide with activity similar to that of enterococcal sex pheromone cAM373, which facilitates intergeneric DNA transfer. J Bacteriol 192: 2535-2545.
22. Kim EB, Kopit LM, Harris LJ, Marco ML (2012) Draft genome sequence of the quality control strain Enterococcus faecalis ATCC 29212. J Bacteriol 194: 6006-6007.
23. Bourgogne A, Garsin DA, Qin X, Singh KV, Sillanpaa J, et al. (2008) Large scale variation in Enterococcus faecalis illustrated by the genome analysis of strain OG1RF. Genome Biol 9: R110.
24. Boneca IG, Chiosis G (2003) Vancomycin resistance: occurrence, mechanisms and strategies to combat it. Expert Opin Ther Targets 7: 311-328. (Pubitemid 36722218)
25. Wilson AP, Cepeda JA, Hayman S, Whitehouse T, Singer M, et al. (2006) In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients. J Antimicrob Chemother 58: 470-473. (Pubitemid 44294970)
26. Weinstein MP (2001) Comparative evaluation of penicillin, ampicillin, and imipenem MICs and susceptibility breakpoints for vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Clin Microbiol 39: 2729-2731.
27. Fuchs PC, Barry AL, Brown SD (2002) In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 49: 467-470. (Pubitemid 34223667)
28. Lemaitre N, Ricard I, Pradel E, Foligne B, Courcol R, et al. (2012) Efficacy of ciprofloxacin-gentamicin combination therapy in murine bubonic plague. PLoS One 7: e52503.
29. Furustrand Tafin U, Majic I, Zalila Belkhodja C, Betrisey B, Corvec S, et al. (2011) Gentamicin improves the activities of daptomycin and vancomycin against Enterococcus faecalis in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother 55: 4821-4827.
30. Eagle H, Musselman AD (1948) The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med 88: 99-131.
31. Kondo N, Kuwahara-Arai K, Kuroda-Murakami H, Tateda-Suzuki E, Hiramatsu K (2001) Eagle-type methicillin resistance: new phenotype of high methicillin resistance under mec regulator gene control. Antimicrob Agents Chemother 45: 815-824. (Pubitemid 32182032)
32. Grandière-Pérez L, Jacqueline C, Lemabecque V, Patey O, Potel G, et al. (2005) Eagle effect in Corynebacterium diphtheriae. J Infect Dis 191: 2118-2120. (Pubitemid 40800583)
33. Shah PM (1982) Paradoxical effect of antibiotics. I. The 'Eagle effect'. J Antimicrob Chemother 10: 259-260.
34. Yourassowsky E, Van der Linden MP, Lismont MJ, Crokaert F, Glupczynski Y (1986) Rate of bactericidal activity for Streptococcus faecalis of a new quinolone, CI-934, compared with that of amoxicillin. Antimicrob Agents Chemother 30: 258-259. (Pubitemid 16038759)
35. Breukink E, de Kruijff B (2006) Lipid II as a target for antibiotics. Nat Rev Drug Discov 5: 321-332.
36. Breukink E, van Heusden HE, Vollmerhaus PJ, Swiezewska E, Brunner L, et al. (2003) Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes. J Biol Chem 278: 19898-19903. (Pubitemid 36799179)
37. Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl H, et al. (1999) Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 286: 2361-2364. (Pubitemid 30016902)
38. Christ K, Wiedemann I, Bakowsky U, Sahl HG, Bendas G (2007) The role of lipid II in membrane binding of and pore formation by nisin analyzed by two combined biosensor techniques. Biochim Biophys Acta 1768: 694-704. (Pubitemid 46275601)
39. Martin NI, Breukink E (2007) Expanding role of lipid II as a target for lantibiotics. Future Microbiol 2: 513-525. (Pubitemid 47578215)
40. Pai MP, Graci DM, Amsden GW (2000) Macrolide drug interactions: an update. Ann Pharmacother 34: 495-513. (Pubitemid 30193784)
41. Hooper DC (2001) Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 7: 337-341.
42. Davis BD (1987) Mechanism of bactericidal action of aminoglycosides. Microbiol Rev 51: 341-350.
43. Tong Z, Zhou L, Jiang W, Kuang R, Li J, et al. (2011) An in vitro synergetic evaluation of the use of nisin and sodium fluoride or chlorhexidine against Streptococcus mutans. Peptides 32: 2021-2026.
44. Tong Z, Zhou L, Li J, Jiang W, Ma L, et al. (2011) In Vitro Evaluation of the Antibacterial Activities of MTAD in Combination with Nisin against Enterococcus faecalis. J Endod 37: 1116-1120.
45. Cottagnoud P, Cottagnoud M, Tauber MG (2003) Vancomycin acts synergistically with gentamicin against penicillin-resistant pneumococci by increasing the intracellular penetration of gentamicin. Antimicrob Agents Chemother 47: 144-147. (Pubitemid 36070355)
46. Scheffers DJ, Pinho MG (2005) Bacterial cell wall synthesis: new insights from localization studies. Microbiol Mol Biol Rev 69: 585-607.
47. Jia J, Zhu F, Ma X, Cao Z, Li Y, et al. (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8: 111-128.
48. Smith AW (2005) Biofilms and antibiotic therapy: is there a role for combating bacterial resistance by the use of novel drug delivery systems? Adv Drug Deliv Rev 57: 1539-1550.
49. Barnes AM, Ballering KS, Leibman RS, Wells CL, Dunny GM (2012) Enterococcus faecalis produces abundant extracellular structures containing DNA in the absence of cell lysis during early biofilm formation. MBio 3: e00193-00112.